Portland

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Amyloidosis2 trials
• Metastatic breast cancer2 trials
• Prostate cancer2 trials
• Dermatomyositis and polymyositis (myositis)1 trial

Phase

• Phase 35 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Completed4 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Alnylam Pharmaceuticals2 trials
• Olema Pharmaceuticals, Inc.2 trials
• Arvinas Androgen Receptor, Inc.1 trial
• Arvinas Inc.1 trial
• Priovant Therapeutics, Inc.1 trial

Running trials

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

  Contact: Olema Pharmaceuticals, Inc.

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

  NCT05437263· Phase 3· Priovant Therapeutics, Inc.· Source

• Completed

  Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

  NCT05177042· Phase 1· Arvinas Androgen Receptor, Inc.· Source

• Completed

  Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT03888612· Phase 1/2· Arvinas Inc.· Source

• Completed

  HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

  NCT03759379· Phase 3· Alnylam Pharmaceuticals· Source